The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder closely related to insulin resistance, obesity, and type 2 diabetes mellitus. While sustained hyperglycemia and insulin resistance are central to the pathogenesis of MASLD, there is growing evidence suggesting that glucose dysregulation in this condition is heterogeneous and dynamic. Glycemic variability (GV), which reflects fluctuations in glucose levels over time, has emerged as a complementary dimension of glucose homeostasis and has been increasingly explored in relation to hepatic steatosis, fibrosis, and cardiometabolic risk. Experimental data indicate that recurrent glucose oscillations promote oxidative stress, inflammatory signaling, and fibrogenic activation, while observational studies have reported associations between short- and long-term GV and MASLD-related phenotypes in diverse populations. The aim of this review is to describe the mechanistic links between insulin resistance, GV, and MASLD, summarize the current clinical and population evidence evaluating GV in this context, and identify key methodological and conceptual gaps that should inform future research.

Keywords

MASLD / glycemic variability / insulin resistance / oxidative stress / type 2 diabetes mellitus

References

[1] Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med. 2025; 393: 683-98.

[2] Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol. 2025; 328: C1637-66.

[3] Liao NH, Wang CY, Lai KY, Kao HH, Lin WY, Chen TP. Association between metabolic dysfunction-associated steatotic liver disease and insulin resistance in individuals with normoglycemia. Medicine (Baltimore). 2025; 104:e44109.

[4] Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026; 335: 163-74.

[5] Budd J, Cusi K. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Curr Diab Rep. 2020; 20: 59.

[6] Han E, Han KD, Lee YH, Kim KS, Hong S, Park JH, et al.; Fatty LiverResearch Group of the Korean Diabetes Association. Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality. Cardiovasc Diabetol. 2025; 24: 289.

[7] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126: 460-8.

[8] Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024; 44: 2538-50.

[9] Byrne CD, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E. Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol. 2025; 22: 314-28.

[10] Ramírez-Mejía MM, Qi X, Abenavoli L, Romero-Gómez M, Eslam M, Méndez-Sánchez N. Metabolic dysfunction: The silenced connection with fatty liver disease. Ann Hepatol. 2023; 28: 101138.

[11] Palma R, Pronio A, Romeo M, Scognamiglio F, Ventriglia L, Ormando VM, et al. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. J Clin Med. 2022; 11: 3649.

[12] Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol. 2023; 29: 3999-4008.

[13] Wang Y, Liu J, Yang Y, Wang Q, Sun Y, Shen R, et al. Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study. Ann Med. 2025; 57: 2548976.

[14] Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One. 2013; 8: e76161.

[15] Hong SH, Lee JS, Kim JA, Lee YB, Roh E, Hee Yu J, et al. Glycemic variability and the risk of nonalcoholic fatty liver disease: A nationwide population-based cohort study. Diabetes Res Clin Pract. 2021; 177: 108922.

[16] Honda F, Hiramatsu A, Hyogo H, Aikata H, Daijo K, Teraoka Y, et al. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS One. 2018; 13: e0195028.

[17] Suh S, Kim JH. Glycemic Variability: How Do We Measure It and Why Is It Important? Diabetes Metab J. 2015; 39: 273-82.

[18] Klimontov VV, Saik OV, Korbut AI. Glucose Variability: How Does It Work? Int J Mol Sci. 2021; 22: 7783.

[19] Wang X, Cao Y. A Narrative Review: Relationship Between Glycemic Variability and Emerging Complications of Diabetes Mellitus. Biomolecules. 2025; 15: 188.

[20] Schiaffini R, Liccardo D, Alisi A, Benevento D, Cappa M, Cianfarani S, et al. Early Glucose Derangement Detected by Continuous Glucose Monitoring and Progression of Liver Fibrosis in Nonalcoholic Fatty Liver Disease: An Independent Predictive Factor? Horm Res Paediatr. 2016; 85: 29-34.

[21] Zhong H, Zhang K, Lin L, Yan Y, Shen L, Chen H, et al. Two-week continuous glucose monitoring-derived metrics and degree of hepatic steatosis: a cross-sectional study among Chinese middle-aged and elderly participants. Cardiovasc Diabetol. 2024; 23: 322.

[22] Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017; 13: 572-87.

[23] Rui L. Energy metabolism in the liver. Compr Physiol. 2014; 4: 177-97.

[24] Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012; 148: 852-71.

[25] Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010; 21: 345-52.

[26] Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014; 510: 84-91.

[27] Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol. 2015; 9: 1055-67.

[28] Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021; 22: 6403.

[29] Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022; 7: 216.

[30] Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci. 2023; 24: 15473.

[31] Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH-role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024; 59: S10-22.

[32] Hutchison AL, Tavaglione F, Romeo S, Charlton M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023; 79: 1524-41.

[33] Yorke E. Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity. Clin Med Insights Endocrinol Diabetes. 2022; 15: 11795514221074672.

[34] Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Compr Physiol. 2020; 10: 785-809.

[35] Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne). 2020; 11: 592373.

[36] Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024; 73: 533-40.

[37] Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017; 13: 509-20.

[38] Li L, Spranger L, Stobäus N, Beer F, Decker AM, Wernicke C, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss-weight maintenance. Nutr Diabetes. 2021; 11: 31.

[39] Meex RC, Hoy AJ, Morris A, Brown RD, Lo JCY, Burke M, et al. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015; 22: 1078-89.

[40] Igudesman D, Yu G, Dauriat C, Roman T, Kashi MR, Blakley E, et al. Microbiota encroachment and a gut-adipose-liver axis in metabolic dysfunction-associated steatotic liver disease. Am J Physiol Gastrointest Liver Physiol. 2025; 329: G201-14.

[41] Ramírez-Mejía MM, Ponciano-Rodríguez G, Méndez-Sánchez N. Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets. Arch Med Res. 2025; 56: 103335.

[42] May KS, den Hartigh LJ. Gut Microbial-Derived Short Chain Fatty Acids: Impact on Adipose Tissue Physiology. Nutrients. 2023; 15: 272.

[43] Münte E, Hartmann P. The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. Biomolecules. 2025; 15: 469.

[44] Peña-Durán E, García-Galindo JJ, López-Murillo LD, Huerta-Huerta A, Balleza-Alejandri LR, Beltrán-Ramírez A, et al. Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders. Int J Mol Sci. 2025; 26: 1773.

[45] Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health. 2019; 38: 81-8.

[46] Goto H, Takamura T. Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. J Obes Metab Syndr. 2025; 34: 224-38.

[47] Jee YM, Lee JY, Ryu T. Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma. Biomedicines. 2025; 13: 1260.

[48] Carter JK, Friedman SL. Hepatic Stellate Cell-Immune Interactions in NASH. Front Endocrinol (Lausanne). 2022; 13: 867940.

[49] Garbuzenko DV. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis. World J Clin Cases. 2022; 10: 3662-76.

[50] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017; 14: 397-411.

[51] Lee WH, Kipp ZA, Bates EA, Pauss SN, Martinez GJ, Hinds TD Jr. The physiology of MASLD: molecular pathways between liver and adipose tissues. Clin Sci (Lond). 2025; 139: 1015-46.

[52] Wang S, Yin J, Liu Z, Liu X, Tian G, Xin X, et al. Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease. Life Sci. 2024; 359: 123211.

[53] Maria Barbalho S, Laurindo LF, Valenti VE, Méndez-Sánchez N, Ramírez-Mejía MM, Goulart RA. Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD-A Narrative Review. Int J Mol Sci. 2025; 26: 11547.

[54] Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025; 13: 134-48.

[55] Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? Cardiovasc Diabetol. 2020; 19: 102.

[56] Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2015; 38: 2354-69.

[57] Yin X, Zheng F, Pan Q, Zhang S, Yu D, Xu Z, et al. Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. J Mol Endocrinol. 2015; 55: 169-81.

[58] Kahl S, Straßburger K, Pacini G, Trinks N, Pafili K, Mastrototaro L, et al. Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity. J Hepatol. 2025; 82: 417-26.

[59] Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295: 1681-7.

[60] Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003; 52: 2795-804.

[61] Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012; 142: 711-25.e6.

[62] Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019; 7: 221-30.

[63] Ceriello A. The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol. 2012; 57: 133-8.

[64] Trivedi P, Wang S, Friedman SL. The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells. Cell Metab. 2021; 33: 242-57.

[65] Yang LX, Qi C, Lu S, Ye XS, Merikhian P, Zhang DY, et al. Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells. Nat Commun. 2025; 16: 524.

[66] González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci. 2023; 24: 9352.

[67] Yang Z, Zhao J, Xie K, Tang C, Gan C, Gao J. MASLD development: From molecular pathogenesis toward therapeutic strategies. Chin Med J (Engl). 2025; 138: 1807-24.

[68] Zhang L, Li Q, Deng Y, Zou Y, Wang L, Li J. Glycolysis to lactylation: Unraveling the metabolic and epigenetic landscape in tissue fibrosis (Review). Mol Med Rep. 2025; 32: 290.

[69] Ramos-Tovar E, Muriel P. Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver. Antioxidants (Basel). 2020; 9: 1279.

[70] Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025; 48: 1057-82.

[71] Ogawa Y, Nakahara T, Ono M, Kawaguchi T, Isoda H, Hiramatsu A, et al. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. J Gastroenterol Hepatol. 2022; 37: 592-9.

[72] Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Curr Diab Rep. 2022; 22: 95-115.

[73] Mannucci E, Ognibene A, Sposato I, Brogi M, Gallori G, Bardini G, et al. Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetol. 2003; 40: 181-6.

[74] American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025; 48: S27-49.

[75] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27: 1487-95.

[76] Agmon O, Sigawi T, Ilan Y. The constrained disorder principle: A novel framework for understanding glycemic variability and optimizing diabetes management. Endocr Metab Sci. 2025; 19: 100262.

[77] Tang XX, Wu R, Chen JH, Wang FL, Zhao SL, Lu J, et al. Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in U.S. adults with MASLD. Metabol Open. 2025; 28: 100402.

[78] Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984; 310: 341-6.

[79] International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32: 1327-34.

[80] Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22: 1462-70.

[81] Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42: 1593-603.

[82] Lundholm MD, Emanuele MA, Ashraf A, Nadeem S. Applications and pitfalls of hemoglobin A1C and alternative methods of glycemic monitoring. J Diabetes Complications. 2020; 34: 107585.

[83] Wang A, Liu X, Xu J, Han X, Su Z, Chen S, et al. Visit-to-Visit Variability of Fasting Plasma Glucose and the Risk of Cardiovascular Disease and All-Cause Mortality in the General Population. J Am Heart Assoc. 2017; 6: e006757.

[84] Martinez M, Santamarina J, Pavesi A, Musso C, Umpierrez GE. Glycemic variability and cardiovascular disease in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2021; 9: e002032.

[85] Ling J, Ng JKC, Chan JCN, Chow E. Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease. Front Endocrinol (Lausanne). 2022; 13: 869899.

[86] Wu X, Zhao X, Chen W, Chen Q, Kong L, Li P. A systematic review of continuous glucose monitoring sensors: principles, core technologies and performance evaluation. Sensor Actuator Rep. 2025; 10: 100361.

[87] Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 19.

[88] Martínez-Mihara MS, Lozano-Martínez P, Mañas-Martínez AB, Gimeno-Orna JA, Sáenz-Abad D. In-Hospital Glycemic Variability and Mean Blood Glucose as Risk Markers for Long-Term Mortality in Patients with Diabetes. J Clin Med. 2025; 14: 8820.

[89] Lin J, Cai C, Xie Y, Yi L. Acute glycemic variability and mortality of patients with acute stroke: a meta-analysis. Diabetol Metab Syndr. 2022; 14: 69.

[90] Hjort A, Iggman D, Rosqvist F. Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis. Clin Nutr. 2024; 43: 915-25.

[91] Sanyal AJ, Husain M, Diab C, Mangla KK, Shoeb A, Lingvay I, et al. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review. Am Heart J Plus. 2024; 41: 100386.

[92] Mustafa A, Kite C, Lagojda L, Dallaway A, Chatha KK, Than NN, et al. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int J Mol Sci. 2025; 26: 11275.

[93] Caturano A, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, et al. Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications. Antioxidants (Basel). 2025; 14: 72.

[94] Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Mehta PD, et al. Cardiovascular Implications in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Korean Circ J. 2026; 56: 103-30.

[95] Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, et al. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes. 2026; 17: 113149.

[96] Lee Y, Lee W. Liver fibrosis index and mortality in metabolic dysfunction-associated steatotic liver disease: a Korean cohort study. Sci Rep. 2025; 16: 950.

[97] Lam R, Jain D, Deng Y, Acharya E, Lim JK. Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort Study. J Clin Transl Hepatol. 2024; 12: 988-96.

[98] Corey K, Mehta A, Mangla KK, Chandramouli AS, Shoeb A, Krarup N, et al. Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH. JHEP Rep. 2025; 8: 101621.

[99] Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021; 74: 1220-33.

[100] Yoo JH, Kang M, Kim G, Hur KY, Kim JH, Sinn DH, et al. Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. J Diabetes Investig. 2021; 12: 1252-62.

[101] Yoo JJ, Cho EJ, Han K, Heo SS, Kim BY, Shin DW, et al. Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study. Cancer Epidemiol Biomarkers Prev. 2021; 30: 974-81.

[102] Zhou H, Zeng X, Xue Y, Wang X, Liu S, Zhu Z, et al. Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Nonalcoholic Fatty Liver Disease in Middle Age. J Clin Endocrinol Metab. 2022; 107: e2301-8.

[103] Barbieri E, Bonet J, Fox D, Nelson R, Nelson MB, Nelson L, et al. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity (Silver Spring). 2025; 33: 116-24.

[104] Yang M, Qi X, Li N, Kaifi JT, Chen S, Wheeler AA, et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023; 14: 228.

[105] Xu Y, Chen D, Yang H, Zhang Y, Huang C, Zhong Y, et al. Glycemic Variability and Gut Microbiota Metabolic Patterns: A Novel Perspective on Diabetic Complications. Food Sci Nutr. 2025; 13: e71242.

[106] Dimova R, Chakarova N, Del Prato S, Tankova T. The Relationship Between Dietary Patterns and Glycemic Variability in People with Impaired Glucose Tolerance. J Nutr. 2023; 153: 1427-38.

[107] Qiu S, Cai X, Sun Z, Li L, Zügel M, Steinacker JM, et al. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol. 2017; 10: 701-13.

[108] Keating SE, Sabag A, Hallsworth K, Hickman IJ, Macdonald GA, Stine JG, et al. Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Med. 2023; 53: 2347-71.

[109] Reutrakul S, Punjabi NM, Van Cauter E. Impact of Sleep and Circadian Disturbances on Glucose Metabolism and Type 2 Diabetes. In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al., editors. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.

[110] Maury E, Ramsey KM, Bass J. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ Res. 2010; 106: 447-62.

[111] Yang J, Zhang K, Xi Z, Ma Y, Shao C, Wang W, et al. Short sleep duration and the risk of nonalcoholic fatty liver disease/metabolic associated fatty liver disease: a systematic review and meta-analysis. Sleep Breath. 2023; 27: 1985-96.

[112] Song E, Kim JA, Roh E, Yu JH, Kim NH, Yoo HJ, et al. Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII. Front Endocrinol (Lausanne). 2021; 12: 647459.

[113] Von-Hafe M, Borges-Canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, et al. Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review. Metabolites. 2022; 12: 298.

[114] Demori I, Grasselli E. The Role of the Stress Response in Metabolic Dysfunction-Associated Fatty Liver Disease: A Psychoneuroendocrineimmunology-Based Perspective. Nutrients. 2023; 15: 795.

[115] Zhou XD, Chen QF, Kim SU, Cheuk-Fung Yip T, Petta S, Nakajima A, et al. Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD. Clin Gastroenterol Hepatol. 2025;[Epub ahead of print].

[116] Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20: 475-85.

[117] Feng G, Wong VW, Targher G, Byrne CD, Zheng MH. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut. 2025; 74: 1741-50.

[118] Ajjan RA. The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control. Diabetes Obes Metab. 2024; 26: 3-16.